Multiple Sclerosis (MS) Drug Market

MedPage Today  11 hrs ago  Comment 
BOSTON (MedPage Today) -- Dietary patterns in women did not appear to influence their risk of developing multiple sclerosis, according to a large study with 2 decades of follow-up.
MedPage Today  Sep 14  Comment 
BOSTON (MedPage Today) -- A biologic drug targeting the granulocyte-macrophage colony stimulating factor was safe and showed hints of activity against brain lesions in multiple sclerosis patients in a phase I trial.
MedPage Today  Sep 14  Comment 
BOSTON (MedPage Today) -- An investigational oral drug for multiple sclerosis with the same mechanism as the approved product fingolimod (Gilenya) was highly effective in a phase II trial with seemingly fewer effects on cardiac function than the...
FierceBiotech  Sep 12  Comment 
Partners Biogen Idec and AbbVie are touting late-stage results for their new, monthly multiple sclerosis treatment, preparing to hand in regulatory applications next year and contend in a crowded market.
MedPage Today  Sep 12  Comment 
BOSTON (MedPage Today) -- Daclizumab HYP cut relapse rates and disability progression in multiple sclerosis patients more effectively than interferon beta-1a (Avonex) in a phase III trial, but liver toxicity with the IL-2 inhibitor reared its head...
MedPage Today  Sep 11  Comment 
BOSTON (MedPage Today) -- A closely watched phase I trial of autologous mesenchymal stem cells (MSCs) for multiple sclerosis proved that the treatment was safe, with some hints that it might have helped some patients on the efficacy side.
MedPage Today  Sep 11  Comment 
BOSTON (MedPage Today) -- A strong correlation between myelin water fraction and clinical disease measures in multiple sclerosis supports a role for the former in patient management and as an outcome measure in clinical trials.
Benzinga  Sep 11  Comment 
Today Biogen Idec (NASDAQ: BIIB) announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY™ (peginterferon beta-1a) were maintained in people with relapsing forms of...
Benzinga  Sep 11  Comment 
Today Biogen Idec (NASDAQ: BIIB) announced that five-year results from the ENDORSE Phase 3 extension study show TECFIDERA^® (dimethyl fumarate) provides strong and sustained efficacy in a broad range of people living with relapsing-remitting...
Motley Fool  Sep 10  Comment 
Receptos' stock is among today's top gainers after it releases additional data on its leading multiple sclerosis drug RPC1063.


Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki